/SNY
SNY Stock - Sanofi
Healthcare|Drug Manufacturers - GeneralNASDAQ
$48.18+0.40%
+$0.19 (+0.40%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.39
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).82
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+16.2%upside
Target: $55.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SNY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$47.70 – $48.66
TARGET (TP)$56.00
STOP LOSS$44.33
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.37
52W High$60.12
52W Low$44.62
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $44.29B | $41.62B | $40.56B | $39.17B | $37.37B |
| Gross Profit | $31.08B | $28.99B | $28.68B | $26.92B | $25.21B |
| Gross Margin | 70.2% | 69.7% | 70.7% | 68.7% | 67.5% |
| Operating Income | $7.25B | $6.96B | $10.16B | $8.13B | $14.11B |
| Net Income | $5.56B | $5.40B | $8.37B | $6.22B | $12.29B |
| Net Margin | 12.6% | 13.0% | 20.6% | 15.9% | 32.9% |
| EPS | $2.19 | $2.15 | $3.19 | $2.49 | $4.91 |
Company Overview
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
41%
Hold / Neutral
9
53%
Sell / Underperform
1
6%
Analyst Consensus🔴 Bearish
7 Bullish10 Neutral/Bearish
Price Targets
$61
Average Target
↑ 25.8% Upside
Now
$55
Low
$61
Average
$65
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Guggenheim | Downgrade | Neutral | - |
| December 8th 2025 | JP Morgan | Downgrade | Neutral | - |
| September 8th 2025 | Morgan Stanley | Upgrade | Overweight | $58 |
| September 2nd 2025 | Deutsche Bank | Upgrade | Buy | - |
| August 8th 2025 | JP Morgan | Upgrade | Overweight | - |
| April 15th 2025 | Exane BNP Paribas | Initiation | Outperform | $65 |
| March 21st 2025 | Goldman | Initiation | Neutral | $65 |
| January 30th 2025 | Deutsche Bank | Upgrade | Hold | - |
| July 26th 2024 | Argus | Reiterated | Buy | $60← $55 |
| January 23rd 2024 | Morgan Stanley | Initiation | Equal Weight | $55 |
| January 16th 2024 | UBS | Resumed | Buy | - |
| December 5th 2023 | JP Morgan | Downgrade | Neutral | - |
| October 30th 2023 | Stifel | Downgrade | Hold | - |
| September 6th 2023 | Berenberg | Upgrade | Buy | - |
| July 14th 2023 | HSBC Securities | Initiation | Buy | - |
Earnings History & Surprises
SNYBeat Rate
72%
Last 18 quarters
Avg Surprise
+2.7%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$1.70
Q4 2025
EPS Surprise History
Q1 24
-5.3%
$0.89vs$0.94
Q2 24
+3.2%
$0.97vs$0.94
Q3 24
+8.1%
$0.93vs$0.86
Q4 24
+16.3%
$1.57vs$1.35
Q1 25
-1.4%
$0.70vs$0.71
Q2 25
+4.4%
$0.94vs$0.90
Q3 25
-6.2%
$0.90vs$0.96
Q4 25
+6.2%
$1.70vs$1.60
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 22, 2026 | — | — | — | — |
Q1 2026 | Jan 29, 2026 | $0.83 | — | — | — |
Q4 2025 | Oct 24, 2025 | $1.60 | $1.70 | +6.2% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $0.96 | $0.90 | -6.2% | ✗ MISS |
Q2 2025 | Apr 24, 2025 | $0.90 | $0.94 | +4.4% | ✓ BEAT |
Q1 2025 | Jan 30, 2025 | $0.71 | $0.70 | -1.4% | ✗ MISS |
Q4 2024 | Oct 25, 2024 | $1.35 | $1.57 | +16.3% | ✓ BEAT |
Q3 2024 | Jul 25, 2024 | $0.86 | $0.93 | +8.1% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $0.94 | $0.97 | +3.2% | ✓ BEAT |
Q1 2024 | Feb 1, 2024 | $0.94 | $0.89 | -5.3% | ✗ MISS |
Q4 2023 | Oct 27, 2023 | $1.37 | $1.39 | +1.5% | ✓ BEAT |
Q3 2023 | Jul 28, 2023 | $1.55 | $0.95 | -38.7% | ✗ MISS |
Q2 2023 | Apr 27, 2023 | $1.10 | $1.16 | +5.5% | ✓ BEAT |
Q1 2023 | Feb 3, 2023 | $0.90 | $0.87 | -3.3% | ✗ MISS |
Q4 2022 | Oct 28, 2022 | $1.34 | $1.44 | +7.5% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $0.87 | $0.92 | +5.7% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $0.94 | $1.09 | +16.0% | ✓ BEAT |
Q1 2022 | Feb 4, 2022 | $0.72 | $0.79 | +9.7% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $1.18 | $1.29 | +9.3% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $0.75 | $0.83 | +10.7% | ✓ BEAT |
Latest News
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralBenzinga•Dec 19, 2025, 07:30 PM•Also: , ,
Sanofi Reaches Agreement With Trump Administration To Reduce Medicine Costs
📈 PositiveBenzinga•Dec 19, 2025, 07:24 PM
Senior Administration Official Says President Trump To Announce Deals With Nine Pharmaceutical Companies To Reduce Drug Prices; Deals Are With Amgen, Bristol Myers Squibb, Roche's GenenTech, Gilead, GSK, Merck, Novartis, Sanofi And Boehringer Ingelheim; Each Manufacturer Agrees To Reduce Prices On Majority Of Medications Sold Through Medicaid; Companies Commit To $150B In New Investment In Manufacturing And R&D In U.S.
📈 PositiveBenzinga•Dec 19, 2025, 07:20 PM•Also: , ,
'Drug Companies Line Up To Make Deals With Trump After Initial Hesitation; At Least Seven Drug Companies Are Set To Announce Price Cuts With Trump At White House On Friday, Including GlaxoSmithKline, Merck And Sanofi' - Washington Post
📈 PositiveBenzinga•Dec 19, 2025, 05:40 PM•Also: ,
Sanofi Secures EU Orphan Designation For Efdoralprin Alfa In Alpha-1 Antitrypsin Deficiency Related Emphysema
📈 PositiveBenzinga•Dec 17, 2025, 06:19 AM
Dren Bio Enters Into Strategic Collaboration With Sanofi For Discovery And Development Of Next-Gen B-Cell Depleting Therapy For Treatment Of Various Autoimmune Diseases
📈 PositiveBenzinga•Dec 15, 2025, 01:09 PM
Sanofi Reports PERSEUS Phase 3 Study Of Tolebrutinib Did Not Meet Primary Endpoint In Primary Progressive Multiple Sclerosis
📉 NegativeBenzinga•Dec 15, 2025, 07:10 AM
Sanofi Expects FDA Review Of Tolebrutinib In Non-Relapsing Secondary Progressive Multiple Sclerosis To Extend Into 2026
➖ NeutralBenzinga•Dec 15, 2025, 07:07 AM
Sanofi Qfitlia And Cablivi Approved By NMPA In China Expanding Care For Rare Hematologic Diseases Including Hemophilia And aTTP
📈 PositiveBenzinga•Dec 11, 2025, 07:37 AM
Guggenheim Downgrades Sanofi to Neutral
➖ NeutralBenzinga•Dec 9, 2025, 12:16 PM
European Medicines Agency Says Sanofi Notifies Shortage Of Insulin Lispro Sanofi (Insulin Lispro 100 Units/ml) Solution For Injection - Cartridges And Pre-Filled Pen
📉 NegativeBenzinga•Dec 8, 2025, 03:59 PM
JP Morgan Downgrades Sanofi to Neutral
📉 NegativeBenzinga•Dec 8, 2025, 01:15 PM
'Suspicions Of Laundering Tax Fraud: Sanofi Headquarters Raided; The Pharmaceutical Giant Is Targeted, Along With Lactalis And AXA, By An Investigation' - Le Monde
📉 NegativeBenzinga•Nov 25, 2025, 03:42 PM
Regeneron And Sanofi's Dupixent Cuts Debilitating Itch And Hives For Patients Who Don't Respond To Antihistamines, EU Approves Dupixent As First New Treatment In A Decade For Severe Chronic Hives
📈 PositiveBenzinga•Nov 25, 2025, 08:03 AM•Also:
Texas Attorney General Paxton Sues Big Pharma Companies Bristol-Myers Squibb And Sanofi For Making Billions While Harming Americans And Failing To Disclose Plavix's Ineffectiveness
📉 NegativeBenzinga•Nov 20, 2025, 08:54 PM•Also:
EMA Recommended Granting Marketing Authorization In EU For Sanofi's Teizeild (Teplizumab) To Delay The Onset Of Stage 3 Type 1 Diabetes In Adults And In Children From 8 Years Of Age With Stage 2 Type 1 Diabetes
📈 PositiveBenzinga•Nov 14, 2025, 11:30 AM
Novavax To Transfer Marketing Authorization Of Nuvaxovid To Sanofi Under FDA Approval; Sanofi To Pay $25M Milestone Payment
📈 PositiveBenzinga•Nov 4, 2025, 11:16 AM•Also:
Sanofi Prices $3B Bond Offering Across Five Tranches With Fixed And Floating Rate Notes Due Between 2027 And 2032
➖ NeutralBenzinga•Oct 28, 2025, 06:16 AM
Sanofi shares are trading higher after the company reported Q3 EPS and sales above expectations.
📈 PositiveBenzinga•Oct 24, 2025, 01:25 PM
Sanofi Maintains 2025 Guidance, Anticipates High Single-Digit Sales Growth At Constant Exchange Rates And Strong Low Double-Digit EPS Rebound
📈 PositiveBenzinga•Oct 24, 2025, 05:47 AM
Frequently Asked Questions about SNY
What is SNY's current stock price?
Sanofi (SNY) is currently trading at $48.18 per share. The stock has moved +0.40% today.
What is the analyst price target for SNY?
The average analyst price target for SNY is $56.00, based on 1 analyst.
What sector is Sanofi in?
Sanofi operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NASDAQ exchange.
What is SNY's market cap?
Sanofi has a market capitalization of $117.38 billion, making it a large-cap company.
Does SNY pay dividends?
No, Sanofi does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMGN
Amgen Inc.
$327.38
Mkt Cap: $176.3B
BMY
Bristol-Myers Squibb Company
$54.19
Mkt Cap: $110.3B
CELG-RI
Bristol-Myers Squibb Company Ce
$0.04
Mkt Cap: $0.1B
CVS
CVS Health Corporation
$77.72
Mkt Cap: $98.7B
GILD
Gilead Sciences, Inc.
$124.29
Mkt Cap: $154.2B
GSK
GSK plc
$48.61
Mkt Cap: $98.8B
HCA
HCA Healthcare, Inc.
$472.98
Mkt Cap: $114.8B
MDT
Medtronic plc
$98.63
Mkt Cap: $126.5B
PFE
Pfizer Inc.
$25.20
Mkt Cap: $143.3B
VRTX
Vertex Pharmaceuticals Incorporated
$456.20
Mkt Cap: $117.1B
Explore stocks similar to SNY for comparison